These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25522788)

  • 1. Physiology-based pharmacokinetics of caspofungin for adults and paediatrics.
    Stader F; Wuerthwein G; Groll AH; Vehreschild JJ; Cornely OA; Hempel G
    Pharm Res; 2015 Jun; 32(6):2029-37. PubMed ID: 25522788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-body physiology-based pharmacokinetics of caspofungin for general patients, intensive care unit patients and hepatic insufficiency patients.
    Yang QT; Zhai YJ; Chen L; Zhang T; Yan Y; Meng T; Liu LC; Chen LM; Wang X; Dong YL
    Acta Pharmacol Sin; 2018 Sep; 39(9):1533-1543. PubMed ID: 29849129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.
    Emami Riedmaier A; Burt H; Abduljalil K; Neuhoff S
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7(Suppl Suppl 7):S132-42. PubMed ID: 27385171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing.
    Hope WW; Seibel NL; Schwartz CL; Arrieta A; Flynn P; Shad A; Albano E; Keirns JJ; Buell DN; Gumbo T; Drusano GL; Walsh TJ
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3714-9. PubMed ID: 17638696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis.
    Würthwein G; Cornely OA; Trame MN; Vehreschild JJ; Vehreschild MJ; Farowski F; Müller C; Boos J; Hempel G; Hallek M; Groll AH
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1664-71. PubMed ID: 23335740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).
    Duan P; Zhao P; Zhang L
    Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):689-705. PubMed ID: 27858342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.
    Sáez-Llorens X; Macias M; Maiya P; Pineros J; Jafri HS; Chatterjee A; Ruiz G; Raghavan J; Bradshaw SK; Kartsonis NA; Sun P; Strohmaier KM; Fallon M; Bi S; Stone JA; Chow JW
    Antimicrob Agents Chemother; 2009 Mar; 53(3):869-75. PubMed ID: 19075070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants.
    Migoya EM; Mistry GC; Stone JA; Comisar W; Sun P; Norcross A; Bi S; Winchell GA; Ghosh K; Uemera N; Deutsch PJ; Wagner JA
    J Clin Pharmacol; 2011 Feb; 51(2):202-11. PubMed ID: 20679501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment.
    Calcagno A; Baietto L; Pagani N; Bertucci R; Rostagno R; D'Avolio A; Di Perri G; De Rosa FG
    Scand J Infect Dis; 2013 Nov; 45(11):882-4. PubMed ID: 23796067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions.
    Izumi S; Nozaki Y; Maeda K; Komori T; Takenaka O; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2015 Feb; 43(2):235-47. PubMed ID: 25414411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.
    Varma MV; Lai Y; Feng B; Litchfield J; Goosen TC; Bergman A
    Pharm Res; 2012 Oct; 29(10):2860-73. PubMed ID: 22638872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.
    Kersting G; Willmann S; Würthwein G; Lippert J; Boos J; Hempel G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):397-405. PubMed ID: 21789689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low penetration of caspofungin into cerebrospinal fluid following intravenous administration of standard doses.
    Strenger V; Farowski F; Müller C; Hofer N; Dornbusch HJ; Sperl D; Lackner H; Benesch M; Urban C
    Int J Antimicrob Agents; 2017 Aug; 50(2):272-275. PubMed ID: 28527634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic uptake of the novel antifungal agent caspofungin.
    Sandhu P; Lee W; Xu X; Leake BF; Yamazaki M; Stone JA; Lin JH; Pearson PG; Kim RB
    Drug Metab Dispos; 2005 May; 33(5):676-82. PubMed ID: 15716364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.
    Würthwein G; Young C; Lanvers-Kaminsky C; Hempel G; Trame MN; Schwerdtfeger R; Ostermann H; Heinz WJ; Cornely OA; Kolve H; Boos J; Silling G; Groll AH
    Antimicrob Agents Chemother; 2012 Jan; 56(1):536-43. PubMed ID: 22083471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction.
    van der Elst KC; Brüggemann RJ; Rodgers MG; Alffenaar JW
    Transpl Infect Dis; 2012 Aug; 14(4):440-3. PubMed ID: 22316392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.
    Undre NA; Stevenson P; Freire A; Arrieta A
    Pediatr Infect Dis J; 2012 Jun; 31(6):630-2. PubMed ID: 22301478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
    Edginton AN; Schmitt W; Willmann S
    Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data.
    Poirier A; Cascais AC; Funk C; Lavé T
    Chem Biodivers; 2009 Nov; 6(11):1975-87. PubMed ID: 19937834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
    Mehta PA; Vinks AA; Filipovich A; Bleesing J; Jodele S; Jordan MB; Marsh R; Tarin R; Edwards S; Fearing D; Lawrence J; Davies SM
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1458-62. PubMed ID: 20546908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.